Dermatology practice gaps: improving medication management

KAUAI, HAWAII – Ophthalmologists’ hydroxychloroquine dosing recommendations to avoid retinopathy have changed.

Here comes bimekizumab, the newest IL-17 inhibitor

KAUAI, HAWAII – “If this holds up in phase 3, it’s going to be a new world for our patients and for us, ” said Craig L. Leonardi, MD.

Get ready for certolizumab for psoriasis

KAUAI, HAWAII – Women of childbearing potential may prefer it.

Make a PEST of your psoriasis patients

KAUAI, HAWAII – Every psoriasis patient should complete the Psoriasis Epidemiology Screening Tool (PEST) for psoriatic arthritis annually.

Immunogenicity concerns for biosimilars so far don’t go beyond originator biologics

But there are few data available on the impact of antidrug antibodies to biosimilars across rheumatic diseases and on switching.

Early ankylosing spondylitis treatment stops transition from inflammatory to bone-forming fatty lesions

“The earlier we treat intensively, the better impact you have on structural outcomes,” according to Dirk Elewaut, MD, PhD.

‘Multimorbidities’ in RA make impact on treatment efficacy, disease activity

The effects of two or more chronic conditions in patients with RA, such as obesity, fibromyalgia, depression, and anxiety, need to be considered in patient management.

Study: TNF inhibitors improve extraintestinal IBD manifestations

SAN DIEGO – Tumor necrosis factor inhibitors improved the extraintestinal manifestations of inflammatory bowel disease (IBD) among more than half of affected patients, according to a national cohort study. “The best response rates were for...

Registry shows no increased cancer risk with biologics for psoriasis

WAIKOLOA, HAWAII – The latest update from the ongoing PSOLAR registry provides “very reassuring” evidence that the use of biologic agents to treat moderate to severe psoriasis doesn’t significantly increase malignancy risk other than for...

Aspirin, hydrochlorothiazide okay in gout

It’s okay in most cases for gout patients to be on thiazide diuretics or low-dose aspirin, so long as hypouricemic therapy is adjusted as needed, according to rheumatologist and Cleveland Clinic professor Dr. Brian F...

Pages